Revenue Recognition and Accounts Receivable (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

The following table presents the Company’s net sales by therapeutic franchise for each of our reportable segments for the three and nine months ended September 30, 2019 and 2018, respectively:



(In millions)	North America		Europe		Rest of World		Total
Three Months Ended September 30, 2019
Central Nervous System & Anesthesia	$	155.5	$	214.3	$	87.0	$	456.8
Infectious Disease	28.7		179.0		270.3		478.0
Respiratory & Allergy	308.5		98.2		66.6		473.3
Cardiovascular	63.3		126.2		41.3		230.8
Gastroenterology	30.0		147.9		95.9		273.8
Diabetes & Metabolism	91.3		68.9		34.2		194.4
Dermatology	38.2		75.8		29.3		143.3
Women’s Healthcare	100.4		60.5		26.1		187.0
Oncology	196.1		22.0		42.8		260.9
Immunology	12.3		20.3		10.3		42.9
Other ⁽¹⁾	64.3		32.8		89.9		187.0
Total	$	1,088.6	$	1,045.9	$	793.7	$	2,928.2

Nine Months Ended September 30, 2019
Central Nervous System & Anesthesia	$	426.4	$	619.3	$	243.9	$	1,289.6
Infectious Disease	77.3		299.7		783.0		1,160.0
Respiratory & Allergy	805.3		327.9		166.5		1,299.7
Cardiovascular	159.1		358.6		116.1		633.8
Gastroenterology	94.9		434.9		276.3		806.1
Diabetes & Metabolism	326.1		208.0		110.4		644.5
Dermatology	77.6		217.7		70.7		366.0
Women’s Healthcare	269.5		165.3		65.4		500.2
Oncology	567.8		59.9		107.0		734.7
Immunology	31.4		41.3		27.6		100.3
Other ⁽¹⁾	199.6		198.1		274.4		672.1
Total	$	3,035.0	$	2,930.7	$	2,241.3	$	8,207.0



(In millions)	North America		Europe		Rest of World		Total
Three Months Ended September 30, 2018
Central Nervous System & Anesthesia	$	154.7	$	219.6	$	92.4	$	466.7
Infectious Disease	63.1		157.8		223.2		444.1
Respiratory & Allergy	161.8		94.8		47.4		304.0
Cardiovascular	95.9		147.3		40.9		284.1
Gastroenterology	24.5		150.0		91.1		265.6
Diabetes & Metabolism	94.9		73.9		43.8		212.6
Dermatology	86.7		62.8		18.0		167.5
Women’s Healthcare	83.1		61.3		28.1		172.5
Oncology	171.0		18.2		31.9		221.1
Immunology	8.0		2.3		10.0		20.3
Other ⁽¹⁾	68.6		53.3		146.9		268.8
Total	$	1,012.3	$	1,041.3	$	773.7	$	2,827.3

Nine Months Ended September 30, 2018
Central Nervous System & Anesthesia	$	554.2	$	665.7	$	251.7	$	1,471.6
Infectious Disease	172.1		280.5		643.8		1,096.4
Respiratory & Allergy	457.3		351.8		147.7		956.8
Cardiovascular	262.4		443.2		126.6		832.2
Gastroenterology	102.5		448.3		249.3		800.1
Diabetes & Metabolism	318.6		227.9		102.1		648.6
Dermatology	265.7		217.4		70.1		553.2
Women’s Healthcare	261.4		198.1		69.5		529.0
Oncology	382.5		55.4		95.6		533.5
Immunology	36.1		7.3		29.1		72.5
Other ⁽¹⁾	185.6		174.7		379.0		739.3
Total	$	2,998.4	$	3,070.3	$	2,164.5	$	8,233.2

____________


⁽¹⁾	Other consists of numerous therapeutic franchises, none of which individually exceeds 5% of consolidated net sales.

Variable Consideration and Accounts Receivable

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three and nine months ended September 30, 2019 and 2018, respectively:



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
(In millions)	2019			2018			2019			2018
Gross sales	$	5,051.5		$	4,861.4		$	13,841.0		$	14,419.0
Gross to net adjustments:
Chargebacks	(913.5		)	(835.7		)	(2,368.8		)	(2,524.2		)
Rebates, promotional programs and other sales allowances	(979.2		)	(1,025.6		)	(2,709.9		)	(3,144.2		)
Returns	(82.3		)	(59.4		)	(203.3		)	(160.5		)
Governmental rebate programs	(148.3		)	(113.4		)	(352.0		)	(356.9		)
Total gross to net adjustments	$	(2,123.3	)	$	(2,034.1	)	$	(5,634.0	)	$	(6,185.8	)
Net sales	$	2,928.2		$	2,827.3		$	8,207.0		$	8,233.2

Schedule of Accounts Receivable, Net

Accounts receivable, net was comprised of the following at September 30, 2019 and December 31, 2018, respectively:



(In millions)	September 30, 2019		December 31, 2018
Trade receivables, net	$	2,546.6	$	2,416.5
Other receivables	401.4		464.5
Accounts receivable, net	$	2,948.0	$	2,881.0